MX2011006095A - Dihidroetorfina y su preparacion. - Google Patents

Dihidroetorfina y su preparacion.

Info

Publication number
MX2011006095A
MX2011006095A MX2011006095A MX2011006095A MX2011006095A MX 2011006095 A MX2011006095 A MX 2011006095A MX 2011006095 A MX2011006095 A MX 2011006095A MX 2011006095 A MX2011006095 A MX 2011006095A MX 2011006095 A MX2011006095 A MX 2011006095A
Authority
MX
Mexico
Prior art keywords
preparation
dihydroetorphines
stereocentre
derivative
alkyl
Prior art date
Application number
MX2011006095A
Other languages
English (en)
Inventor
Steve Whitelock
Deborah Phyllis Harding
Carl David Turner
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011006095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0822342A external-priority patent/GB0822342D0/en
Priority claimed from GB0920699A external-priority patent/GB0920699D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2011006095A publication Critical patent/MX2011006095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14

Abstract

La presente invención proporciona un proceso para la preparación de un compuesto de fórmula (VI) o una sal o derivado de lo mismo, (Ver fórmula (VI)) en donde R1 y R2 son independientemente alquilo de 1 a 8 átomos de carbono y * representa un estereocentro.
MX2011006095A 2008-12-08 2009-12-04 Dihidroetorfina y su preparacion. MX2011006095A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0822342A GB0822342D0 (en) 2008-12-08 2008-12-08 Dihydroetorphine
GB0920699A GB0920699D0 (en) 2009-11-26 2009-11-26 Dihydroetorphine
PCT/GB2009/051655 WO2010067101A1 (en) 2008-12-08 2009-12-04 Dihydroetorphines and their preparation

Publications (1)

Publication Number Publication Date
MX2011006095A true MX2011006095A (es) 2011-09-22

Family

ID=42046251

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011006095A MX2011006095A (es) 2008-12-08 2009-12-04 Dihidroetorfina y su preparacion.
MX2014015079A MX359363B (es) 2008-12-08 2009-12-04 Dihidroetorfina y su preparacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014015079A MX359363B (es) 2008-12-08 2009-12-04 Dihidroetorfina y su preparacion.

Country Status (32)

Country Link
US (4) US20120010231A1 (es)
EP (2) EP3018133A1 (es)
JP (2) JP5787764B2 (es)
KR (2) KR20170082665A (es)
CN (2) CN104119349B (es)
AR (1) AR074545A1 (es)
AU (1) AU2009326196B2 (es)
CA (1) CA2745537C (es)
CL (1) CL2011001363A1 (es)
CY (1) CY1116875T1 (es)
DK (1) DK2370443T3 (es)
EA (1) EA022210B1 (es)
ES (1) ES2548881T3 (es)
HK (1) HK1161720A1 (es)
HR (1) HRP20151138T1 (es)
HU (1) HUE025913T2 (es)
IL (1) IL213207B (es)
ME (1) ME02262B (es)
MX (2) MX2011006095A (es)
MY (1) MY159913A (es)
NZ (1) NZ593102A (es)
PA (1) PA8852801A1 (es)
PL (1) PL2370443T3 (es)
PT (1) PT2370443E (es)
RS (1) RS54309B1 (es)
SG (1) SG171456A1 (es)
SI (1) SI2370443T1 (es)
SM (1) SMT201500273B (es)
TW (2) TWI541246B (es)
UY (1) UY32295A (es)
WO (1) WO2010067101A1 (es)
ZA (1) ZA201104161B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541246B (zh) * 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
ES2748803T3 (es) 2012-12-31 2020-03-18 Rhodes Tech Procedimiento para preparar 6,14-etenomorfinanos sustituidos en 7, 6,14-etanomorfinanos sustituidos en 7
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP3023427A1 (en) * 2014-11-19 2016-05-25 Siegfried AG Improved method of manufacturing buprenorphine and analogues thereof from oripavine
EP3067357A1 (en) * 2015-03-11 2016-09-14 Siegfried AG Method of manufacturing stereoisomers of buprenorphine and analogues thereof
GB201513442D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal patch
GB201513441D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal delivery system
CN114105875B (zh) * 2021-12-06 2023-11-03 四川大学 一种***衍生物二氢埃托啡的合成方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB925723A (en) 1960-09-05 1963-05-08 J F Macfarlan & Company Ltd Novel thebaine derivatives
GB937214A (en) 1961-06-02 1963-09-18 J F Macfarlan & Company Ltd Oripavine derivatives
JPS59184182A (ja) 1983-04-02 1984-10-19 Res Inst For Prod Dev ３−ベンゾイルチオ−４、５α−エポキシ−７α−〔１（Ｒ）−ヒドロキシ−１−メチルベンチル〕−６−メトキシ−１７−メチル−６、１４−エンド−エタノモルヒナン
JPS62153214A (ja) 1985-12-26 1987-07-08 Nitto Electric Ind Co Ltd 医薬製剤
JPS62281815A (ja) 1986-05-27 1987-12-07 Teisan Seiyaku Kk 貼付剤及びその製造法
JPS63201119A (ja) 1987-02-17 1988-08-19 Kao Corp 貼付剤組成物
US4891377A (en) 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
PT95069B (pt) 1989-08-24 1997-10-31 Searle & Co Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
JPH08504189A (ja) 1992-09-21 1996-05-07 キン、ボーイ 低／非たんでき性オピオイド鎮痛剤の確認及び使用方法
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
PL181582B1 (pl) 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
KR100204659B1 (ko) * 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
JPH10231248A (ja) 1997-02-19 1998-09-02 T T S Gijutsu Kenkyusho:Kk ジヒドロエトルフィン含有経皮吸収型製剤
DK1039882T3 (da) 1998-08-27 2011-01-24 Pfizer Health Ab Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
WO2001080796A1 (en) 2000-04-26 2001-11-01 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
CA2386794A1 (en) 2000-07-13 2002-01-24 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
ATE341552T1 (de) 2001-08-10 2006-10-15 Neuro Therapeutics Ltd Derivate morphinähnlicher opioidverbindungen
CN1233645C (zh) * 2001-09-14 2005-12-28 中国人民解放军军事医学科学院毒物药物研究所 新的东罂粟碱衍生物及其医药用途
EP1476155A4 (en) 2002-01-23 2009-10-28 Univ California METHODS AND COMPOSITIONS FOR REDUCING THE DEVELOPMENT OF DRUG TOLERANCE AND / OR PHYSICAL DEPENDENCE
US20060177381A1 (en) 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1509210A1 (de) 2002-05-28 2005-03-02 LABTEC GESELLSCHAFT FüR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBH Pflaster, enthaltend fentanylum
KR101407131B1 (ko) 2002-06-10 2014-06-19 유로-셀티크 소시에떼 아노뉨 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
WO2004017941A2 (en) 2002-08-20 2004-03-04 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
AU2002951965A0 (en) 2002-10-09 2002-10-24 Monash University Amidine compounds
TWI296531B (en) 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US20040208917A1 (en) 2003-04-16 2004-10-21 Wilfried Fischer Transdermal systems for the release of clonidine
EP1641441B1 (en) 2003-04-30 2014-03-12 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US20050113365A1 (en) 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
CN100500151C (zh) 2004-04-02 2009-06-17 北京万全阳光医药科技有限公司 一种水溶性药物舌下给药制剂
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
WO2006110642A2 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
CA2604696C (en) 2005-04-15 2015-03-24 Interface Biologics, Inc. Polymer-biologically active agent complexes for localized delivery of said biologically active agent
KR100764679B1 (ko) 2005-07-22 2007-10-09 익수제약 주식회사 파록세틴을 함유하는 경피투여용 패취제
US8163701B2 (en) 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents
WO2007052308A2 (en) 2005-11-03 2007-05-10 Brain N' Beyond Biotech Pvt. Ltd. Glyco-phosphorylated biologically active agents
GB0523031D0 (en) 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN101370486B (zh) 2005-12-09 2012-12-05 北京康倍得医药技术开发有限公司 含有硝酸异山梨酯和比索洛尔的透皮贴剂
US20080039775A1 (en) 2006-03-15 2008-02-14 Alza Corporation Apparatus and Method for Transdermal Delivery of Parathyroid Hormone Agents to Prevent or Treat Osteopenia
USD576282S1 (en) 2006-06-16 2008-09-02 Activatek, Inc. Adhesive transdermal medicament patch
USD625017S1 (en) 2006-08-11 2010-10-05 Hisamitsu Pharmaceutical Co., Inc. Medical transdermal patch
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
CN100512817C (zh) 2006-11-15 2009-07-15 闫章年 复方噻拉嗪注射液及制备工艺
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
JP2010514789A (ja) 2006-12-27 2010-05-06 アベール ファーマシューティカルズ インコーポレイテッド 副腎皮質ステロイド投与のための経皮的方法及びパッチ
EP2137189B1 (en) * 2007-03-06 2015-05-06 Mallinckrodt LLC Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
KR100929560B1 (ko) 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
EP2298277A1 (en) 2009-09-09 2011-03-23 Labtec GmbH Transdermal patch formulation
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)

Also Published As

Publication number Publication date
PA8852801A1 (es) 2010-04-21
PL2370443T3 (pl) 2016-01-29
IL213207B (en) 2018-01-31
CA2745537C (en) 2017-01-17
AU2009326196A2 (en) 2012-08-30
US20160115174A1 (en) 2016-04-28
CN104119349B (zh) 2017-04-12
TWI541246B (zh) 2016-07-11
HRP20151138T1 (hr) 2015-11-20
TW201531476A (zh) 2015-08-16
RS54309B1 (en) 2016-02-29
MY159913A (en) 2017-02-15
TWI630208B (zh) 2018-07-21
US20170267687A1 (en) 2017-09-21
PT2370443E (pt) 2015-10-23
CA2745537A1 (en) 2010-06-17
EA201170781A1 (ru) 2012-01-30
NZ593102A (en) 2013-10-25
IL213207A0 (en) 2011-07-31
HK1161720A1 (en) 2012-08-03
EP2370443B1 (en) 2015-08-05
SI2370443T1 (sl) 2015-12-31
JP5787764B2 (ja) 2015-09-30
US20120010231A1 (en) 2012-01-12
EA022210B1 (ru) 2015-11-30
AR074545A1 (es) 2011-01-26
US9206190B2 (en) 2015-12-08
US9481681B2 (en) 2016-11-01
CN104119349A (zh) 2014-10-29
JP6151307B2 (ja) 2017-06-21
CN102307877A (zh) 2012-01-04
UY32295A (es) 2010-06-30
SG171456A1 (en) 2011-07-28
DK2370443T3 (en) 2015-11-09
CL2011001363A1 (es) 2011-09-23
SMT201500273B (it) 2016-01-08
EP3018133A1 (en) 2016-05-11
CN102307877B (zh) 2015-12-16
US10745406B2 (en) 2020-08-18
US20150133483A1 (en) 2015-05-14
KR20110098801A (ko) 2011-09-01
JP2015157864A (ja) 2015-09-03
MX359363B (es) 2018-09-26
EP2370443A1 (en) 2011-10-05
CY1116875T1 (el) 2017-04-05
AU2009326196B2 (en) 2016-08-11
AU2009326196A1 (en) 2011-06-23
JP2012510985A (ja) 2012-05-17
ES2548881T3 (es) 2015-10-21
KR101992272B1 (ko) 2019-06-24
ME02262B (me) 2016-02-29
TW201022274A (en) 2010-06-16
HUE025913T2 (en) 2016-04-28
WO2010067101A1 (en) 2010-06-17
ZA201104161B (en) 2016-05-25
KR20170082665A (ko) 2017-07-14

Similar Documents

Publication Publication Date Title
MX359363B (es) Dihidroetorfina y su preparacion.
MX2009007077A (es) Analogos de ciclopamina.
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
PH12013500365A1 (en) Anti-infective agents and uses thereof
UA96961C2 (uk) Азаадамантанові похідні і способи застосування
MX2009005616A (es) Derivados de pirido-pirazina utiles como compuestos herbicidas.
MX344153B (es) Proceso para la preparación de sales de pirrolidinio.
WO2012101011A3 (en) New aryl-benzocycloalkyl amide derivatives
WO2008155615A3 (en) An improved process for the preparation of cephalosporin antibiotic
MX2011011776A (es) Nuevos profarmacos de triptolite.
JO3067B1 (ar) بيرميدينات بيرازولو امينو كمثبطات ل fak
MX2012013332A (es) Preparacion de intermediarios de posaconazol.
MY169267A (en) New aryl-quinoline derivatives
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX2009009490A (es) Profarmacos novedosos.
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
HK1124842A1 (en) Methods of preparing imidazole-based compounds
MY160882A (en) Biocidal composition and method
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
IN2012DN03104A (es)
MX2013009388A (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).
IN2012DN02000A (es)
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
MX2009010850A (es) Sintesis de ibandronato en multiples etapas.
GB2511240A (en) Nitrofurfuryl substituted phenyl linked piperidino-oxadiazoline conjugates as anti-tubercular agents and process for the preparation thereof

Legal Events

Date Code Title Description
FG Grant or registration